dc.contributor.author | Petrushkin, H | en_US |
dc.contributor.author | Rogers, D | en_US |
dc.contributor.author | Pavesio, C | en_US |
dc.date.accessioned | 2017-02-20T10:03:13Z | |
dc.date.available | 2016-12-05 | en_US |
dc.date.issued | 2018 | en_US |
dc.date.submitted | 2017-02-14T17:15:36.162Z | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/19440 | |
dc.description.abstract | The use of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema is controversial. In this letter, we review the literature and report our results from a retrospective case series of 281 patients taking topical nepafenac 0.1% for uveitic cystoid macular edema between 2010 and 2016. Over a 4-month period, there was a modest improvement in best-corrected visual acuity (0.66 ± 3.7 logMAR) and central macular thickness (69.8 ± 132.5 μm). Patients with idiopathic anterior uveitis and HLA-B*27-associated anterior uveitis recovered more vision while taking topical nepafenac 0.1%, than those with other uveitides, however, this was not statistically significant. There is a need for controlled prospective studies to evaluate the efficacy of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema. At present, clinicians have little evidence on which to base practice. | en_US |
dc.format.extent | 795 - 797 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Ocul Immunol Inflamm | en_US |
dc.rights | This is an Accepted Manuscript of an article published by Taylor & Francis in Ocular Immunology and Inflammation on 12 Jan 2017, available online: http://www.tandfonline.com/10.1080/09273948.2016.1269931. | |
dc.subject | Cystoid macular edema | en_US |
dc.subject | NSAIDs | en_US |
dc.subject | nepafenac | en_US |
dc.subject | nevanac | en_US |
dc.subject | non-steroidal anti-inflammatory drugs | en_US |
dc.subject | uveitic | en_US |
dc.subject | uveitis | en_US |
dc.subject | Administration, Topical | en_US |
dc.subject | Anti-Inflammatory Agents, Non-Steroidal | en_US |
dc.subject | Benzeneacetamides | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Macula Lutea | en_US |
dc.subject | Macular Edema | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Phenylacetates | en_US |
dc.subject | Tomography, Optical Coherence | en_US |
dc.subject | Uveitis | en_US |
dc.subject | Visual Acuity | en_US |
dc.title | The Use of Topical Non-steroidal Anti-inflammatory Drugs for Uveitic Cystoid Macular Edema. | en_US |
dc.type | Article | |
dc.rights.holder | © 2017 Informa UK Limited. | |
dc.identifier.doi | 10.1080/09273948.2016.1269931 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/28080174 | en_US |
pubs.issue | 5 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 26 | en_US |
qmul.funder | The Genetic Basis of KIR3DL1 - HLA-B*51 interactions in Behcet's Disease::The Royal College of Ophthalmology / Pfizer Fellowship | en_US |
qmul.funder | The Genetic Basis of KIR3DL1 - HLA-B*51 interactions in Behcet's Disease::The Royal College of Ophthalmology / Pfizer Fellowship | en_US |